Laboratory Surveillance of Invasive Pneumococcal Disease in Australia, 2003 — predicting the future impact of the universal childhood conjugate vaccine program
DOI:
https://doi.org/10.33321/cdi.2004.28.49Keywords:
invasive pneumococcal disease, vaccination, surveillanceAbstract
A comprehensive invasive pneumococcal disease (IPD) laboratory surveillance program was carried out in Australia in 2003. This program provided data on the prevalence of pneumococcal serotypes and antimicrobial resistance. There were 1,995 isolates tested with 34 per cent (683) from children aged less than five years and 27 per cent (535) from the elderly aged more than 65 years. One thousand eight hundred and sixty were isolates from blood, 79 from CSF and 56 from other sterile sites. In young children, 84 per cent of isolates were a serotype and 92 per cent a serogroup in the 7-valent pneumococcal conjugate vaccine (7vPCV). Of penicillin resistant isolates in children less than five years of age 85 per cent and 98 per cent were a serotype and serogroup in the 7vPCV respectively. When the universal 7vPCV vaccine program in young children is introduced in 2005, a proportion of cases of IPD should also be prevented in young adults (estimated reduction of 54 cases annually) and elderly Australians (an estimated reduction of 110 cases annually) as a result of improved herd immunity. Pneumococcal serotypes with higher rates of penicillin resistance (19F, 14 and 6B) were more prevalent in the elderly than in young children. In contrast, erythromycin resistance was more common in children less than five years of age (24%) compared to the elderly (15%). The predominant serotype with erythromycin resistance in Australia was serotype 14 and thus there is likely to be a major reduction in erythromycin resistance as a result of 7vPCV vaccination. Continued surveillance of pneumococcal serotype distribution and antibiotic susceptibility will be essential in order to identify serotype replacement by non-vaccine serotypes and to monitor the overall impact of current and future vaccine programs on invasive pneumococcal disease in Australia, not only in young children but also in other age groups. Commun Dis Intell 2004;28:455 464.
Downloads
References
Kertesz DA, Di Fabio JL, de Cunto Brandileone MC, Castaneda E, Echaniz-Aviles G, Heitmann I, et al. Invasive Streptococcus Pneumoniae Infection in Latin American Children: Results of the Pan American Health Organization Surveillance Study. Clin Infect Dis 1998 Jun;26:1355–1361.
Jette LP, Lamothe F. Surveillance of Invasive Streptococcus Pneumoniae Infection in Quebec, Canada, From 1984 to 1986: Serotype Distribution, Antimicrobial Susceptibility, and Clinical Characteristics. J Clin Microbiol 1989;27:1–5.
Nielsen SV, Henrichsen J. Capsular Types of Streptococcus Pneumoniae Isolated From Blood and CSF During 1982–1987. Clin Infect Dis 1992;15:794–798.
Voss L, Lennon D, Okesene-Gafa K, Ameratunga S, Martin D. Invasive Pneumococcal Disease in a Pediatric Population, Auckland, New Zealand. Pediatr Infect Dis J 1994;13:873–878.
McIntyre PB, Gilmour RE, Gilbert GL, Kakakios AM, Mellis CM. Epidemiology of Invasive Pneumococcal Disease in Urban New South Wales, 1997–1999. Med J Aust 2000;173 Suppl:S22–S26.
Krause VL, Reid SJ, Merianos A. Invasive Pneumococcal Disease in the Northern Territory of Australia, 1994–1998. Erratum Appears in MJA 2001;174:309. Med J Aust 2000;173 Suppl:S27–S31.
Hogg GG, Strachan JE, Lester RA. Invasive Pneumococcal Disease in the Population of Victoria. Med J Aust 2000;173 Suppl:S32–S35.
VISN. Are Current Recommendations for Pneumococcal Vaccination Appropriate for Western Australia? The Vaccine Impact Surveillance Network—Invasive Pneumococcal Study Group. Med J Aust 2000;173 Suppl:S36–S40.
Andresen DN, Collignon PJ. Invasive pneumococcal disease in the Australian Capital Territory and Queanbeyan region: do high infant rates reflect more disease or better detection? J Paediatr Child Health 2004;40:184–188.
Turnidge JD, Bell JM, Collignon PJ. Rapidly Emerging Antimicrobial Resistances in Streptococcus Pneumoniae in Australia. Pneumococcal Study Group. Med J Aust 1999;170:152–155.
Watson M, Bayley K, Bell JM, Gilbert GL, Hogg G, Keil AD, et al. Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002 – implications for vaccine serotype coverage. Comm Dis Intell 2003;27:478–487.
Roche P, Krause V, Bartlett M, Coleman D, Cook H, Counahan M, et al. Invasive pneumococcal disease in Australia, 2003. Comm Dis Intell 2004;28:441–454
Lund E, Henrichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae. In Bergan T, Norris R. eds Methods in Microbiology, Volume 12 Acadamic Press, London, 1978, pp241–262.
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine. N Engl J Med 2003;348:1737–1746.
National Committee for Clinical Laboratory Standards. Preformance Standards for Antimicrobial disk susceptibility tests;approved standards. 8th edition, NCCLS document, m2–A8, Villanova, 2003.
Bell SM, Gatus BJ, Pham JN, Rafferty DL. Antibiotic susceptibility testing by the CDS method. A manual for medical and veterinary laboratories. The Antibiotic Reference Laboratory, South Eastern Area Laboratory Services, 2002.
E-test Technical Manual. Technical Guide 5C:Susceptibility testing of pneumococci, 2000.
National Health and Medical Research Council. The Australian Immunisation Handbook 8th Edition. National Health and Medical Research Council. 2003 pp 143–152.
Downloads
Published
How to Cite
License
Copyright (c) 2004 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
